Ignite Creation Date:
2024-05-05 @ 7:02 PM
Last Modification Date:
2024-10-26 @ 9:41 AM
Study NCT ID:
NCT00593554
Status:
TERMINATED
Last Update Posted:
2018-04-10
First Post:
2008-01-04
Brief Title:
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
Sponsor:
Sherif S Farag
Organization:
Indiana University
Study Overview
Official Title:
A Phase II Trial of Haplotype Mismatched Hematopoietic Stem Cell Transplantation Using Highly Purified CD34 Cells in Patients With Hematological Malignancies
Status:
TERMINATED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Slow accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if haplotype-mismatched HSCT is associated with an improvement in treatment-related mortality TRM rate at 6 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None